Psych CASC / OSCE · Emergency psychiatry
Lithium toxicity counselling — CASC communication station
MRCPsych/FRANZCP-style communication station: explain lithium toxicity, interaction precipitants, sick-day rules, EXTRIP-level seriousness without jargon overload, and shared restart decision including anti-suicide context.
On this page & tools
Target exams
Station brief
Format. Communication and psychoeducation station, approximately 7–10 minutes after reading time. You are the psychiatry registrar on the medical ward. [1]
Candidate instructions. Explain what lithium toxicity is in plain language, why ibuprofen and dehydration mattered, what warning symptoms to report, how blood tests are timed, and how the team will decide about restarting lithium. Involve the partner’s concerns about safety without inventing legal statutes. Avoid false reassurance and avoid permanent nihilism. [2][4]
Candidate scenario
Patient: “They said my lithium nearly poisoned me because of Nurofen. Does that mean lithium is too dangerous forever? My partner is terrified.” Partner: “Should we throw all the lithium away tonight?” Observations stable; last level falling toward therapeutic range off drug. [1]
Marking domains
- Clear explanation of toxicity as clinical illness from high lithium effect, not moral failure
- Accurate precipitants: NSAID + illness/dehydration (and mention ACEI/thiazides as related future risks)
- Warning symptoms: coarse tremor, unsteadiness, slurred speech, vomiting, confusion — seek urgent care
- Monitoring: timed blood tests (12-hour trough concept for maintenance), sick-day rules
- Balanced restart discussion: lithium can still be the best long-term option for many people, including mood stability and reduced suicide risk, only after kidneys recover and with a safety plan
- Collaborative plan; check understanding; no invented EXTRIP jargon unless asked and then simplified
Reveal assessor key
Open. Introduce role, check privacy, ask what they already understand, acknowledge fear. [1]
Explain mechanism simply. Lithium is cleared by the kidneys. Ibuprofen and dehydration make the kidneys hold on to lithium, so levels climb even on a previously safe dose. That is why she developed shaking, unsteadiness and confusion. [2]
What we did medically. Stopped lithium and the ibuprofen, checked blood and kidney tests, gave fluids, watched closely; dialysis is used when people are much more unwell or kidneys cannot clear lithium safely — she did not need to hear every EXTRIP number unless she asks. [3]
Warning signs and sick days. If vomiting, diarrhoea, fever with poor intake, coarse tremor, slurred speech, confusion — seek urgent help and do not keep taking lithium until advised. Avoid unsupervised anti-inflammatories; ask pharmacist/doctor before new blood-pressure or pain medicines. [1][2]
Restart decision. Not forever banned by default. Lithium remains one of the most effective long-term treatments for bipolar disorder and has evidence for lowering suicide risk. Restart only after recovery, with blood monitoring and a written plan — shared decision, not a demand to destroy all tablets tonight without a replacement plan. [4][5]
Close. Summarise three take-home points, offer written information, arrange follow-up with psychiatrist/GP, check teach-back. [1]
References
- [1]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
- [2]Finley PR Drug Interactions with Lithium: An Update Clin Pharmacokinet, 2016.PMID 26936045
- [3]Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup Clin J Am Soc Nephrol, 2015.PMID 25583292
- [4]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
- [5]Nolen WA, Licht RW, Young AH, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium Bipolar Disord, 2019.PMID 31112628